Texas Biomedical Research Institute

Texas Biomed with the University of Alabama at Birmingham and Aridis Pharmaceuticals develop a neutralizing human monoclonal antibody against SARS-CoV-2

hmAb targeting SARS-CoV-2 shows efficacy in lab and hamster models with direct delivery to the lungs

Newswise — SAN ANTONIO, TEXAS (October 19, 2020)Texas Biomedical Research Institute (Texas Biomed) Professor Luis Martinez-Sobrido, Ph.D., recently released study findings, alongside colleagues at the University of Alabama at Birmingham and Aridis Pharmaceuticals, Inc. indicating that a human monoclonal antibody (hmAb) 1212C2 showed promise for further clinical development for preventative use or as a therapy for SARS-CoV-2, the virus that causes COVID-19. Earlier this year, the consortium of scientists isolated specific B cells from patients infected with SARS-CoV-2 and developed a panel of hmAbs that not only bind to SARS-CoV-2 infected cells, but also neutralize the ability of the virus to infect cells. The hmAb 1212C2 was subsequently licensed to Aridis Pharmaceuticals.

Taking the study a step further, the scientists have shown, as outlined in the study on BioRxiv, that delivering hmAb 1212C2 directly to the lung through inhalation using Aridis’ proprietary formulation and plasma half-life extension, or by injection showed significant reduction in viral load in the lungs.

Antibodies are proteins produced by the body’s immune system to fight off infections. Monoclonal antibodies are commercially or experimentally produced antibodies derived from the original antibody producing cell. Scientists worldwide have shown that the Receptor Binding Domain (RBD) region of SARS-CoV-2’s Spike protein is a key target for any drug that aims to stop the virus from attaching to cells through the human angiotensin converting enzyme 2 (ACE2) protein. If the virus can’t attach to the cell, it can’t infect and propagate.  The hmAbs were discovered by the labs of Dr. James Kobie and Dr. Mark Walter at the University of Alabama at Birmingham in collaboration with Dr. Martinez-Sobrido.

In both lab and animal experiments, hmAb 1212C2 produced a preventative and therapeutic effect against SARS-CoV-2. In hamster models, delivering formulated and plasma half-life extended hmAb 1212C2 through a nebulizer at low dosage produced a significant reduction of the virus and lessened disease progression in the lungs.

“These are critical findings as we look to develop vaccines and therapies that are not only effective, but also efficiently manufactured and easily administered to patients,” Dr. Martinez-Sobrido explained.

Nearly 40 million people globally have contracted COVID-19 with more than one million deaths, and the worldwide pandemic is not slowing down. Neutralizing antibodies developed either by natural infection or through vaccination, or administered as a therapeutic are critical to the overall protection of the human population.

“Administering targeted human antibodies that bind tightly to SARS-CoV-2 is a promising approach to advance therapies. We must have more effective therapies to reduce the death rate from this ongoing pandemic. I am excited about the opportunity to advance hmAb 1212C2 with Aridis Pharmaceuticals,” said Dr. Larry S. Schlesinger, President/CEO of Texas Biomed.

The cohort of scientists licensed hmAb 1212C2 to Aridis for further development as both a possible prophylactic for preventing COVID-19 and as a treatment for COVID-19, while also looking at opportunities to use this hmAb in combination with other hmAbs, or with other antiviral therapies.

Staff in Dr. Luis Martinez-Sobrido’s lab who contributed to this research include Jun-Gyu Park, Fatai Oladunni, Chengjin Ye and Kevin Chiem.


Texas Biomed is one of the world’s leading independent biomedical research institutions dedicated to eradicating infection and advancing health worldwide through innovative biomedical research. Texas Biomed partners with researchers and institutions around the world to develop vaccines and therapeutics against viral pathogens causing AIDS, hepatitis, hemorrhagic fever, tuberculosis and parasitic diseases responsible for malaria and schistosomiasis disease. The Institute has programs in host-pathogen interaction, disease intervention and prevention and population health to understand the links between infectious diseases and other diseases such as aging, cardiovascular disease, diabetes and obesity. For more information on Texas Biomed, go to www.TxBiomed.org.


Filters close

Showing results

110 of 4146
Newswise: Long-Term Impacts of COVID-19: Your Mental Health
Released: 25-Nov-2020 2:15 PM EST
Long-Term Impacts of COVID-19: Your Mental Health

The COVID-19 pandemic has shaped more than half a year of our lives, canceling plans, upending livelihoods and causing feelings of grief, stress and anxiety. And Cedars-Sinai mental health experts say the pandemic could be shaping our mental health well into the future.

Released: 25-Nov-2020 12:45 PM EST
SARS-CoV-2 mutations do not appear to increase transmissibility
University College London

None of the mutations currently documented in the SARS-CoV-2 virus appear to increase its transmissibility in humans, according to a study led by UCL researchers.

Newswise: COVID-19 vaccine candidate tested preclinically at UAB nears first clinical test in people
Released: 25-Nov-2020 11:05 AM EST
COVID-19 vaccine candidate tested preclinically at UAB nears first clinical test in people
University of Alabama at Birmingham

Maryland-based Altimmune Inc., a clinical stage biopharmaceutical company, has submitted an Investigational New Drug, or IND, application to the United States Food and Drug Administration to commence a Phase 1 clinical study of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.

Released: 25-Nov-2020 11:05 AM EST
BIDMC researchers reveal how genetic variations are linked to COVID-19 disease severity
Beth Israel Lahey Health

New research BIDMC-led sheds light on the genetic risk factors that make individuals more or less susceptible to severe COVID-19.

Newswise: blog-pandemic-scenario-planning-lg-feature2.jpg
Released: 25-Nov-2020 11:05 AM EST
Pandemic Ups Game on Scenario Planning in The Arts
Wallace Foundation

Researcher/Author of new toolkit and report seeks to help arts and culture organizations add scenario planning to their strategic toolbox

Released: 25-Nov-2020 10:30 AM EST
Young people's anxiety levels doubled during first COVID-19 lockdown, says study
University of Bristol

The number of young people with anxiety doubled from 13 per cent to 24 per cent, during the early stages of the COVID-19 pandemic and lockdown 1, according to new research from the University of Bristol.

Newswise: 249837_web.jpg
Released: 25-Nov-2020 10:20 AM EST
Tracking COVID-19 trends in hard-hit states
Louisiana State University

Currently, there are over 10 million confirmed cases and more than 240,000 casualties attributed to COVID-19 in the U.S.

Released: 25-Nov-2020 9:55 AM EST
More Health Systems Join National #MaskUp Campaign
Cleveland Clinic

Many more health systems are joining the national #MaskUp campaign encouraging Americans to stop the spread of COVID-19 by following safety guidelines. Over just a few days, another 19 health systems with hundreds of hospitals united with 100 health systems nationwide with hospitals numbering in the thousands. The public service campaign is critical to the health and well-being of all Americans. It is a plea from healthcare professionals everywhere: wear a mask and follow other precautions to save lives and help get our country back on its feet.

Newswise: delaterre_jpeg.jpg
Released: 25-Nov-2020 7:35 AM EST
Warwick scientists design model to predict cellular drug targets against Covid-19
University of Warwick

The covid-19 virus, like all viruses relies on their host for reproduction

access_time Embargo lifts in 2 days
Embargo will expire: 30-Nov-2020 10:00 AM EST Released to reporters: 24-Nov-2020 5:35 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 30-Nov-2020 10:00 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Showing results

110 of 4146